-
Product Insights
New![]()
Net Present Value Model: AstraZeneca Plc’s PRS-060
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Prometheus Biosciences Inc’s PR-200
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Eli Lilly and Co’s PR-001
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Eli Lilly and Co’s PR-006
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
Presidente Aleman PR Field, Mexico
Presidente Aleman PR upstream field is located in Veracruz, Mexico. The upstream field is owned by Petroleos Mexicanos. It is operated by Petroleos Mexicanos. The project started its operations in 2008. Presidente Aleman PR Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital and operating costs. We also provide...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PR-001 in Parkinson’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PR-001 in Parkinson's DiseaseDrug Details:PR-001 is under development for the treatment of Parkinson's disease with GBA1...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PRS-344 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRS-344 in Solid Tumor Drug Details: PRS-344 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PRS-346 in Metastatic Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PRS-346 in Metastatic MelanomaDrug Details:PRS-346 is under development for the treatment of metastatic solid tumors like...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PRS-346 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PRS-346 in Solid TumorDrug Details:PRS-346 is under development for the treatment of metastatic solid tumors like...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PRS-346 in Malignant Mesothelioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PRS-346 in Malignant MesotheliomaDrug Details:PRS-346 is under development for the treatment of metastatic solid tumors like...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PR-15 in Acute Coronary Syndrome
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PR-15 in Acute Coronary Syndrome Drug Details: PR-15 (revacept, GPVI-Fc) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PR-006 in Frontotemporal Dementia (FTD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PR-006 in Frontotemporal Dementia (FTD)Drug Details:PR-006 is under development for the treatment of frontotemporal dementia with...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PRS-220 in Idiopathic Pulmonary Fibrosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PRS-220 in Idiopathic Pulmonary Fibrosis Drug Details:PRS-220 is under development for the treatment of idiopathic pulmonary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PRS-346 in Metastatic Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PRS-346 in Metastatic Pancreatic CancerDrug Details:PRS-346 is under development for the treatment of metastatic solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PRS-346 in Metastatic Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PRS-346 in Metastatic Colorectal CancerDrug Details:PRS-346 is under development for the treatment of metastatic solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PR-001 in Gaucher Disease Type II
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PR-001 in Gaucher Disease Type IIDrug Details:PR-001 is under development for the treatment of Parkinson's disease...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PR-001 in Gaucher Disease Type I
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PR-001 in Gaucher Disease Type I Drug Details:PR-001 is under development for the treatment of Parkinson's...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Potassium Bicarbonate + Potassium Citrate) Pr in Cystinuria
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.(Potassium Bicarbonate + Potassium Citrate) Pr in CystinuriaDrug Details: Potassium citrate and potassium bicarbonate (Sibnayal) is a...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PRS-346 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PRS-346 in Non-Small Cell Lung CancerDrug Details:PRS-346 is under development for the treatment of metastatic solid...
-
Product Insights
DER Parana – PR 323 Highway Duplication – Parana
Equip yourself with the essential tools needed to make informed and profitable decisions with our DER Parana - PR 323 Highway Duplication - Parana report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.